Truist Financial
MRSN

Truist Financial’s Mersana Therapeutics MRSN Stock Holding History

Truist Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-668
Closed -$104K – 2782
2021
Q4 		$104K Hold
668
– – ﹤0.01% 2675
2021
Q3 		$157K Hold
668
– – ﹤0.01% 2610
2021
Q2 		$227K Buy
668
+200
+43% +$75.7K ﹤0.01% 2533
2021
Q1 		$189K Hold
468
– – ﹤0.01% 2511
2020
Q4 		$311K Hold
468
– – ﹤0.01% 2133
2020
Q3 		$218K Buy
+468
New +$236K ﹤0.01% 2219

Other funds holding MRSN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return